 The present observational study aimed to compare the efficacy of azacitidine ( AZA<ORGANIZATION> ) and intensive chemotherapy ( IC ) in elderly patients with untreated acute myeloid leukemia ( AML<ORGANIZATION> ), diagnosed according to WHO<ORGANIZATION> criteria. In the two groups, we evaluated complete remission ( CR ), overall survival ( OS ), and disease-free survival ( DFS<ORGANIZATION> ). The AZA<ORGANIZATION> group included 89 patients ; median age was 73 years ( range 61-80 ) and median white blood cell count ( WBCc<ORGANIZATION> ) 2.5 Ã— 10